Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

Rajan Sharma; Alicia Norman; Martin Hoyle; Henry Cutler

Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

Rajan Sharma (Contributor), Alicia Norman (Contributor), Martin Hoyle (Contributor), Henry Cutler (Contributor)

Research output: Book/Report › Commissioned report

Original language	English
Publisher	Australian Government Department of Health
Commissioning body	Medical Services Advisory Committee, Australian Government
Number of pages	21
Publication status	Published - 2020

Cite this

@book{55c567b847b54fe99778a44abfd30ad6,

title = "Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi{\textregistered} (encorafenib), in patients with metastatic colorectal cancer (stage IV)",

author = "Rajan Sharma and Alicia Norman and Martin Hoyle and Henry Cutler",

year = "2020",

language = "English",

publisher = "Australian Government Department of Health",

}

Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV). / Sharma, Rajan (Contributor); Norman, Alicia (Contributor); Hoyle, Martin (Contributor) et al.
Australian Government Department of Health, 2020. 21 p.

Research output: Book/Report › Commissioned report

TY - BOOK

T1 - Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

A2 - Sharma, Rajan

A2 - Norman, Alicia

A2 - Hoyle, Martin

A2 - Cutler, Henry

PY - 2020

Y1 - 2020

UR - http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1617-public

M3 - Commissioned report

BT - Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

PB - Australian Government Department of Health

ER -

Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

Other files and links

Improving health and spending money wisely: evaluating medical tests, devices, procedures for the Australian Government

Cite this

Ratified PICO 1617: BRAF V600 testing to help determine eligibility for PBS access to Braftovi® (encorafenib), in patients with metastatic colorectal cancer (stage IV)

Other files and links

Impacts

Improving health and spending money wisely: evaluating medical tests, devices, procedures for the Australian Government

Cite this